156 related articles for article (PubMed ID: 27663208)
1. Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety.
Pinheiro SP; Rivera DR; Graham DJ; Freedman AN; Major JM; Penberthy L; Levenson M; Bradley MC; Wong HL; Ouellet-Hellstrom R
Ann Epidemiol; 2016 Nov; 26(11):735-740. PubMed ID: 27663208
[TBL] [Abstract][Full Text] [Related]
2. Centralized access to cancer registries.
Deapen D
Ann Epidemiol; 2016 Nov; 26(11):754-756. PubMed ID: 27837787
[TBL] [Abstract][Full Text] [Related]
3. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS
BMJ; 2017 May; 357():j1680. PubMed ID: 28468750
[No Abstract] [Full Text] [Related]
4. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
5. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
6. Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.
Finkelstein JB
J Natl Cancer Inst; 2007 Jan; 99(2):104-7. PubMed ID: 17227990
[No Abstract] [Full Text] [Related]
7. Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort Study.
Tau N; Yahav D; Shepshelovich D
Ann Intern Med; 2020 Sep; 173(6):445-449. PubMed ID: 32716700
[TBL] [Abstract][Full Text] [Related]
8. The Fate of FDA Postapproval Studies.
Woloshin S; Schwartz LM; White B; Moore TJ
N Engl J Med; 2017 Sep; 377(12):1114-1117. PubMed ID: 28930510
[No Abstract] [Full Text] [Related]
9. Cancer drugs remain FDA approved despite lack of benefit, study finds.
McCarthy M
BMJ; 2016 Dec; 355():i6568. PubMed ID: 27923801
[No Abstract] [Full Text] [Related]
10. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
[No Abstract] [Full Text] [Related]
11. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
Wallach JD; Ciani O; Pease AM; Gonsalves GS; Krumholz HM; Taylor RS; Ross JS
BMC Med; 2018 Mar; 16(1):45. PubMed ID: 29562926
[TBL] [Abstract][Full Text] [Related]
12. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.
Nagai S; Ozawa K
Invest New Drugs; 2018 Jun; 36(3):487-495. PubMed ID: 29453626
[TBL] [Abstract][Full Text] [Related]
13. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
Milne CP; Cohen JP; Felix A; Chakravarthy R
Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
[TBL] [Abstract][Full Text] [Related]
14. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
15. Study Highlights the Need for Continuing Postapproval Drug Monitoring.
Stockwell S
Am J Nurs; 2017 Aug; 117(8):16. PubMed ID: 28749872
[TBL] [Abstract][Full Text] [Related]
16. Spending on postapproval drug safety.
Ridley DB; Kramer JM; Tilson HH; Grabowski HG; Schulman KA
Health Aff (Millwood); 2006; 25(2):429-36. PubMed ID: 16522583
[TBL] [Abstract][Full Text] [Related]
17. Two-stage drug approval would reduce the risks.
Frantz JA
Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
[No Abstract] [Full Text] [Related]
18. Postapproval drug surveillance and the first principle of medicine.
Camilleri M; Podolsky DK
Gastroenterology; 2001 Jan; 120(1):5. PubMed ID: 11208707
[No Abstract] [Full Text] [Related]
19. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
[TBL] [Abstract][Full Text] [Related]
20. Preapproval and postapproval availability of published comparative efficacy research on biological agents.
Thomas RH; Freeman MK; Hughes PJ
Am J Health Syst Pharm; 2013 Jul; 70(14):1250-5. PubMed ID: 23820463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
